Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC9 | O60706 | 1/20 | 0.59 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.59 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.59 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CXCR2 | P25025 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.39 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.36 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.34 |
| ▸ | STK4 | Q13043 | 1/20 | 0.33 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.32 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8768944 | 0.87 | GAA (0.50) | ABCC9ABCC8KCNJ11KCNJ8GAA | |
| SCHEMBL6105640 | 0.86 | GAA (0.62) | ABCC9ABCC8KCNJ11KCNJ8GAA | |
| SCHEMBL8670859 | 0.85 | GAA (0.48) | ABCC9ABCC8KCNJ11KCNJ8GAA | |
| SCHEMBL7898502 | 0.81 | ABCC9 (0.41) | ABCC9ABCC8KCNJ11KCNJ8GAA | |
| SCHEMBL6642520 | 0.80 | POLB (0.63) | ABCC9ABCC8KCNJ11KCNJ8GAA | |
| SCHEMBL8768090 | 0.78 | POLB (0.51) | GAAPOLBCXCR2MAPTRXFP1 | |
| SCHEMBL6024203 | 0.74 | ABCC9 (1.00) | ABCC9ABCC8KCNJ11KCNJ8CXCR2 | |
| SCHEMBL4258934 | 0.74 | ABCC9 (1.00) | ABCC9ABCC8KCNJ11KCNJ8CXCR2 | |
| SCHEMBL8414608 | 0.74 | ABCC9 (0.36) | ABCC9ABCC8KCNJ11KCNJ8GAA | |
| SCHEMBL8870947 | 0.72 | ABCC9 (0.72) | ABCC9ABCC8KCNJ11KCNJ8CXCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2010509-B1 | 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE DERIVATIVES AS POTASSIUM CHANNEL OPENERS | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-03 | — | — | EP | disclosed |
| US-20090312412-A1 | 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE DERIVATIVES AS POTASSIUM CHANNEL OPENERS | LANTER JAMES C | 2009-12-17 | — | — | US | disclosed |
| EP-0796243-B1 | DIAMINOCYCLOBUTENE-3,4-DIONES | AMERICAN HOME PROD (US) | 1999-01-27 | — | — | EP | disclosed |
| EP-0729457-B1 | DIAMINOCYCLOBUTENE-3,4-DIONES AS SMOOTH MUSCLE RELAXANTS | AMERICAN HOME PROD (US) | 1998-12-23 | — | — | EP | disclosed |
| EP-0796243-A1 | DIAMINOCYCLOBUTENE-3,4-DIONES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1997-09-24 | — | — | EP | disclosed |
| EP-0789690-A1 | N-ARYL AND N-HETEROARYL-1,2-DIAMINOCYCLOBUTENE-3,4-DIONES WITH SMOOTH MUSCLE RELAXING ACTIVITIES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1997-08-20 | — | — | EP | disclosed |
| US-5605909-A | REDUCING ADVERSE EFFECTS OF SMOOTH MUSCLE CONTRACTIONS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1997-02-25 | — | — | US | disclosed |
| EP-0729457-A1 | DIAMINOCYCLOBUTENE-3,4-DIONES AS SMOOTH MUSCLE RELAXANTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-09-04 | — | — | EP | disclosed |
| US-5532245-A | TO REDUCE SMOOTH MUSCLE CONTRACTIONS; TREATMENT FOR URINARY INCONTINENCE, IRITABLE BOWEL SYNDROME | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-07-02 | — | — | US | disclosed |
| US-5530025-A | SMOOTH MUSCLE RELAXANTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-06-25 | — | — | US | disclosed |
| WO-1996015103-A1 | DIAMINOCYCLOBUTENE-3,4-DIONES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-05-23 | — | — | WO | disclosed |
| WO-1996014300-A1 | N-ARYL AND N-HETEROARYL-1,2-DIAMINOCYCLOBUTENE-3,4-DIONES WITH SMOOTH MUSCLE RELAXING ACTIVITIES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-05-17 | — | — | WO | disclosed |
| US-5506252-A | MUSCLE RELAXANTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-04-09 | — | — | US | disclosed |
| US-5466712-A | Smooth muscle relaxants | AMERICAN HOME PRODUCTS CORPORATION (US) | 1995-11-14 | — | — | US | disclosed |
| WO-1995014005-A1 | DIAMINOCYCLOBUTENE-3,4-DIONES AS SMOOTH MUSCLE RELAXANTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1995-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312412-A1 | 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE DERIVATIVES AS POTASSIUM CHANNEL OPENERS | KCNJ2, KCNN3, KCNN2 | ABCC9 395/4885ABCC8 250/4885KCNJ11 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.